Tarsus Pharmaceuticals, Inc. (TARS)
80.28
+3.39
(+4.41%)
USD |
NASDAQ |
Nov 13, 16:00
80.40
+0.12
(+0.15%)
After-Hours: 19:59
Tarsus Pharmaceuticals Shareholders Equity (Quarterly) : 104.03M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 104.03M |
| June 30, 2026 | 346.73M |
| March 31, 2026 | 348.95M |
| December 31, 2025 | 343.43M |
| September 30, 2025 | 335.08M |
| June 30, 2025 | 332.61M |
| March 31, 2025 | 342.46M |
| December 31, 2024 | 224.53M |
| September 30, 2024 | 237.48M |
| June 30, 2024 | 252.25M |
| March 31, 2024 | 275.21M |
| December 31, 2023 | 196.99M |
| September 30, 2023 | 213.66M |
| June 30, 2023 | 147.73M |
| Date | Value |
|---|---|
| March 31, 2023 | 173.40M |
| December 31, 2022 | 192.90M |
| September 30, 2022 | 202.63M |
| June 30, 2022 | 221.50M |
| March 31, 2022 | 149.20M |
| December 31, 2021 | 166.73M |
| September 30, 2021 | 179.14M |
| June 30, 2021 | 192.47M |
| March 31, 2021 | 183.23M |
| December 31, 2020 | 165.98M |
| September 30, 2020 | 85.33M |
| June 30, 2020 | 52.37M |
| March 31, 2020 | |
| December 31, 2019 | 57.40M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 23.40B |
| Amneal Pharmaceuticals, Inc. | 531.26M |
| Harmony Biosciences Holdings, Inc. | 1.072B |
| ANI Pharmaceuticals, Inc. | 637.11M |
| Corcept Therapeutics, Inc. | 833.74M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 505.50M |
| Total Liabilities (Quarterly) | 401.47M |
| Debt to Equity Ratio | 0.8523 |
| Current Ratio | 1.961 |
| Net Debt Paydown Yield | -0.08% |